Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 1.00 |
| ▸ | PPARG | P37231 | 17/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561793 | 1.00 | PPARA (1.00) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7169665 | 0.91 | PPARA (0.83) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7166687 | 0.90 | PPARA (0.81) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7168930 | 0.87 | PPARA (0.77) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7167912 | 0.84 | PPARA (0.72) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7191771 | 0.82 | PPARA (0.69) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL6820050 | 0.81 | PPARA (0.68) | PPARAPPARGPPARD | |
| SCHEMBL18644967 | 0.81 | PPARA (0.67) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7171462 | 0.80 | PPARA (0.67) | PPARAPPARGNR1H2NR1H3PPARD | |
| SCHEMBL7169654 | 0.79 | PPARA (0.65) | PPARAPPARGNR1H2NR1H3PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12516321-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12486503-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-1581497-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1635641-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-7060705-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1635641-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1581497-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004112699-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040259826-A1 | Mitotic kinesin inhibitors | MERCK & CO., INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004058148-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-6569879-B2 | Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma; benzisoxazole compounds; e.g. ((5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy)acetic acid, methyl ester | MERCK & CO., INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020173663-A1 | Aryloxyacetic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173663-A1 | Aryloxyacetic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885NR1H2 27/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PPARA 4662/4885PPARG 4438/4885NR1H2 245/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | PPARA 456/4885PPARG 405/4885NR1H2 3273/4885 |
| US-20040259826-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | PPARA 3951/4885PPARG 3857/4885NR1H2 2810/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | PPARA 3780/4885PPARG 3888/4885NR1H2 2043/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | PPARA 2387/4885PPARG 3339/4885NR1H2 1545/4885 |
| US-12583871-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PPARA 4312/4885PPARG 4292/4885NR1H2 887/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PPARA 4775/4885PPARG 4662/4885NR1H2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.